HR Execs on the Move

Neopharm Labs

www.neopharmlabs.com

 
As a trusted partner to leaders in the pharmaceutical and life sciences industry for over 30 years, we`ve built a reputation for quality, problem‑solving capabilities, and a superior customer experience. We`re proud to play an integral role in bettering the lives of the global community.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Caroline Khouzam
Director of Human Resources Profile

Similar Companies

myMatrixx

myMatrixx is a full-service pharmacy benefit management (PBM) and ancillary services company focused on workers’ compensation. By combining advanced technology and proactive clinical management throughout the claims process, myMatrixx delivers a Fast, Simple, Effective solution with proven Results. Founded in 2001 by Steven MacDonald, an industry veteran in workers’ compensation, myMatrixx began as a pharmacy benefit manager. Today services include a corporately-owned and operated mail service pharmacy with compounding, ancillary services and DME, and proactive clinical programs. With a focus on workers’ compensation, myMatrixx serves self-insured employers, third party administrators, managed care companies, as well as workers’ compensation and auto insurance companies. From the beginning, we have put the client at the center of everything we do. Their success is our success, and delivering an unimaginably great customer experience is our goal.  

Specialty Operations Solutions

Specialty Operations Solutions, Inc. is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Synthonics

Synthonics is a Blacksburg, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ALLETE PHARMACEUTICALS

ALLETE PHARMACEUTICALS is a Danville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tobira Therapeutics

Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.